Today: 24 April 2026
Subscribe
Browse Category

NASDAQ:XE 24 April 2026

Stock Market Today

  • Israel-Lebanon ceasefire, Microsoft buyouts, and Regeneron drug discounts highlight markets
    April 24, 2026, 9:12 AM EDT. Stock futures mixed after major indexes fall. An extended Israel-Lebanon ceasefire and hopes of U.S.-Iran peace talks lower crude oil prices. President Trump orders U.S. Navy to target boats laying mines in the Strait of Hormuz, where a naval standoff continues. Microsoft launches voluntary buyouts for 7% of U.S. staff, marking a first, alongside Meta's 10% job cuts and Nike trimming 1,400 mainly tech roles. Regeneron joins pharmaceutical companies reducing drug prices after White House deals, offering discounts and free gene therapy for hearing loss, reflecting ongoing U.S. efforts to ease healthcare costs.

Latest article

Amazon-Backed X-Energy’s $1 Billion IPO Puts Nuclear Power Back in the AI Spotlight

Amazon-Backed X-Energy’s $1 Billion IPO Puts Nuclear Power Back in the AI Spotlight

24 April 2026
X-energy raised about $1.02 billion in an upsized IPO, pricing 44.25 million shares at $23 each, 21% above the marketed range. Trading under “XE” on Nasdaq was set to begin Friday. The company has not yet delivered a commercial Xe-100 reactor or reached final investment decisions. Amazon anchored a prior $500 million financing round for X-energy.
Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

24 April 2026
Regeneron shares rose 2.6% Thursday after the company announced a U.S. drug-pricing agreement and said it would offer its new Otarmeni gene therapy free in the U.S. The stock closed at $766.02, up for the week and month but down 1.3% year to date. Raymond James and Cantor Fitzgerald reiterated bullish ratings and high price targets ahead of first-quarter results due April 29.
P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit

P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit

24 April 2026
Procter & Gamble reported fiscal Q3 net sales of $21.2 billion, up 7%, and core earnings per share of $1.59, beating estimates. Organic sales rose 3%, the strongest in over a year, with beauty volumes up 5%. The company warned higher commodity and tariff costs tied to Middle East conflict will weigh on fiscal 2026 earnings, now expected at the low end of its range. P&G shares rose 2% in premarket trading.
Go toTop